Clinical trial of acetylcysteine effervescent tablets in the treatment of obstructive sleep apnea hypopnea syndrome
10.13699/j.cnki.1001-6821.2017.21.004
- VernacularTitle:乙酰半胱氨酸泡腾片治疗阻塞性睡眠呼吸暂停低通气综合征的临床研究
- Author:
Can-Can WANG
1
;
Yue-Juan FENG
;
Dong-Wei YU
;
Xue-Yuan CHEN
Author Information
1. 杭州师范大学附属医院呼吸科
- Keywords:
acetylcysteine effervescent tablet;
obstructive sleep apnea hypopnea syndrome;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(21):2104-2106
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of acetylcysteine effervescent tablets in the treatment of obstructive sleep apnea hypopnea syndrome (OSAHS).Methods One hundred patients with OSAHS were divided into control group and treatment group with 50 cases per group.Control group was given the conventional treatment with low flow oxygen absorption,functional exercise and diet.Treatment group was given acetylcysteine effervescent tablet 600 mg,qd,oral,on the basis of control group.Two groups were treated for 12 weeks.The clinical efficacy,serum endothelin-1 (ET-1),nitric oxide (NO),interleukin-6 (IL-6),tumor necrosis factor-α (TNF-α) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 90.00％ (45 cases/50 cases) and 74.00％ (37 cases/50 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:ET-1 were (39.24 ±5.50) and (46.28 ±0.12)ng · L-1,NO were (56.25 ±7.05) and (48.88 ±5.60)μmol · L-1,IL-6 were (41.48 ±4.91) and (65.77 ±9.10)ng · L-1,TNF-α were (28.37 ±3.42) and (42.32 ± 6.21) ng · L-1,the differences were statistically significant (all P ＜ 0.05).There were no adverse drug reactions occurred between two groups.Conclusion Acetylcysteine effervescent tablet has a definitive clinical efficacy and safety in the treatment of OSAHS,which can adjust the levels of ET-1,NO,IL-6 and TNF-α.
